



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

An exploration of the characteristics of COVID-19 patients referred to a central cardiology hospital with acute coronary syndrome

Amir Savarrakhsh, Arsalan Salari, Seyedeh Fatemeh Mirrazeghi, Azin Vakilpour, Saman Maroufizadeh, Rouhollah Fallah Abadi, Seyed Mehdi Mousavi



PII: S0019-4832(21)00464-8

DOI: <https://doi.org/10.1016/j.ihj.2021.12.013>

Reference: IHJ 1971

To appear in: *Indian Heart Journal*

Received Date: 21 September 2021

Revised Date: 29 December 2021

Accepted Date: 30 December 2021

Please cite this article as: Savarrakhsh A, Salari A, Mirrazeghi SF, Vakilpour A, Maroufizadeh S, Abadi RF, Mousavi SM, An exploration of the characteristics of COVID-19 patients referred to a central cardiology hospital with acute coronary syndrome, *Indian Heart Journal*, <https://doi.org/10.1016/j.ihj.2021.12.013>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Cardiological Society of India. Published by Elsevier B.V.

An exploration of the characteristics of COVID-19 patients referred to a central cardiology hospital with acute coronary syndrome

Amir Savarrakhsh¹, Arsalan Salari^{1,*}, Seyedeh Fatemeh Mirrazeghi¹, Azin Vakilpour¹, Saman Maroufizadeh², Rouhollah Fallah Abadi¹, Seyed Mehdi Mousavi¹

¹ Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

² Department of Biostatistics, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran.

Corresponding Author:

Arsalan Salari, Professor of Interventional Cardiology

Email: gums.icrc@gmail.com

Tel: +98-01333665874

Address: Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, 15 khordad street, District 2, Rasht, Guilan province, Iran.

An exploration of the characteristics of COVID-19 patients referred to a central cardiology hospital with acute coronary syndrome

Abstract:

This study aimed to evaluate the clinical features of COVID-19 patients diagnosed with acute coronary syndrome (ACS). After obtaining patients' demographic and clinical data, ECG and transthoracic echocardiography were performed for all 228 patients. On average, patients aged 63.23 years. The most common underlying disease was hypertension (59.2%). The most common ECG abnormalities in COVID-19 patients with ACS were ST-T changes and pathological Q wave, and 12.3% experienced atrial fibrillation. According to the Multiple logistic regression analysis, a significant relationship between on admission tachycardia and left ventricular ejection fraction with in-hospital mortality was found (OR=24.06, 95% CI: 4.63- 125.11, OR=0.92, 95% CI: 0.087- 0.98).

Keywords: Acute Coronary Syndrome, COVID-19, Electrocardiography

1.Introduction

Although respiratory involvement is the primary clinical manifestation of COVID-19, it can affect various organs leading to a variety of complications, prominently cardiac damage and coagulation disorders.¹ Earlier investigation on COVID-19 patients indicated that the history of underlying cardiovascular disease(CVD) is a negative prognostic factor.² Accordingly, the case fatality rate in COVID-19 patients with no underlying disease is 0.9%, while comorbidities such as CVD, hypertension (HTN), and diabetes mellitus (DM) substantially increase the mortality rate.² At least 20% of critically ill COVID-19 patients experience cardiac injuries. Of note, this infection can cause cardiac problems even in patients without a history of CVD.³ Certain ethnicities and racial groups are disproportionately influenced by COVID-19 disease.⁴ Because of differences in demographic and genetic characteristics of the various populations, the generalizability of previously reported pathophysiological parameters to COVID-19 patients may be limited. Therefore, this study aimed to evaluate the clinical, electrocardiographic, and echocardiographic features of COVID-19 patients diagnosed with acute coronary syndrome (ACS) in a central cardiology hospital in the north of Iran.

2.Methods

In this observational study, 228 consecutive ACS patients with COVID-19 disease confirmed by a positive reverse transcription-polymerase chain reaction test who were admitted from 02/2020-08/2020 were included. The diagnosis of the ACS was performed based on classical triage of ACS (Typical signs and symptoms of cardiac ischemia, electrocardiographic changes including ST-segment elevation or depression (including J-point elevation in multiple leads), T-wave tenting or inversion, and pathologic Q waves, in addition to assessing cardiac biomarkers) by the physician in charge. Patients' demographic and clinical information was collected by a physician of the team. Patients were admitted to ICU if vital signs and oxygen saturation were difficult to maintain or if lung infection progressed quickly. Vital signs were charted every 4 hours. A 12 lead electrocardiography(ECG) was performed for every subject at admission and was repeated when clinically indicated during hospitalization. Transthoracic echocardiography was performed on the entire population by an expert cardiologist using the 2Dimensional echo of Siemens device. The study protocol was in accordance with the 2013 Helsinki Declaration and was approved by the ethics committee of our University. (Code number: 1399.582). Informed consent for participation was obtained from all subjects.

Multiple logistic regression analysis was also applied to examine the relationships of clinical and demographic characteristics with ICU admission and in-hospital mortality. Data analysis was carried out using SPSS version 16.0. The level of significance was set at 0.05.

4.Results

The description of baseline characteristics is shown in table 1. Of the 228 patients, the mean(SD) age was 63.23(13.59), and 54.8% were male. The most common clinical symptoms of COVID-19 disease were dyspnea (58.3%), nausea/vomiting (20.2%), and cough (12.3%). The mean(SD) length of hospital stay was 9.28(7.38) days (range:1 to 45 days). Of the total, 16(0.7%) were admitted to the ICU due to the disease aggravation, and 16(0.7%) died in hospital.

Echocardiographic and ECG characteristics are shown in Table 2. The mean \pm SD of left ventricular ejection fraction(LVEF) of patients in the ICU and deceased group was significantly lower than survived and non-ICU groups ($P<0.001$). Seventy-one percent of patients showed ST-segment changes (42.1% ST-elevation). Pathological Q wave was significantly higher in ICU patients than in the non-ICU group ($P=0.005$). Multiple logistic regression analysis showed that the chance of ICU admission in patients with tachycardia (OR=11.11, 95% CI: 1.93-63.78), and patients who had pathological Q-wave was higher (OR=6.52, 95% CI;1.49-28.43). The chance of ICU admission and death decreased with increasing EF (OR=0.93, 95% CI:0.95- 0.99, $P=0.024$, OR=0.93, 95% CI:0.87- 0.98, $P=0.012$). A significant relationship between tachycardia and LVEF with mortality was also found (OR=24.06, 95% CI: 4.63- 125.11). (Supplementary Table 1)

5. Discussion

The most common clinical symptoms in the studied population were dyspnea, nausea/vomiting, and cough. Nearly half of the patients had two or more comorbidities, of which HTN was the most common one. An initial cohort study on COVID-19 characteristics in China revealed that the most common symptoms in COVID-19 patients at presentations were cough, fatigue, and fever.⁵ Another large case series of COVID-19 patients in the USA reported that 30% of patients presented with fever, 20% with hypoxia, and 12.2% needed mechanical ventilation.⁶ Concordantly, according to previous research, common underlying comorbidities in COVID-19 patients included HTN, DM, and coronary artery diseases, respectively.^{7, 8} In the present study, severe COVID-19 patients had significantly lower blood pressure (BP) at the admission compared to the non-severe group. Similarly, one previous study on critical COVID-19 patients showed that those admitted with hypotension and those who developed persistent hypotension developed critical status consequently. The primary reason for low BP can be a septic shock due to severe infection. Also, other reversible causes of low BP include fever, sweating, and inadequate intake leading to hypovolemia and electrolyte imbalance.⁹

ECG changes for COVID-19 patients demonstrate several cardiovascular alterations ranging from ST-T changes to rhythm disorders, acute pulmonary thromboembolism, and acute myocarditis.¹⁰

In the present study, the most common ECG abnormality in COVID-19 patients with ACS were ST-T changes and pathological Q waves. Moreover, atrial fibrillation (AF) was the most common

observed arrhythmia. Previous studies provided a prevalence of acute myocardial infarction(MI) of 12% in their cohort as defined by either high sensitivity-troponin or CK-MB > 99th percentile or new ECG and echocardiographic abnormalities.¹¹ It is unclear whether the increase in cardiac biomarkers is linked to viral myocarditis, plaque rupture secondary to virus-induced inflammatory response, or a type 1 MI.¹² Also, based on the results of similar studies, it was suggested that MI might be a marker of more severe infection and not causally related.⁸ In line with our findings, earlier research demonstrated that AF appeared to be the most reported arrhythmia with COVID-19 patients, with a prevalence of up to 50% in patients requiring intensive care¹³. This finding spotlight the consideration for long-term anticoagulant treatment. Further, patients of the present study seemed to have severely reduced EF, and nearly half of the population had left ventricular (LV) systolic dysfunction. The mean EF of patients in the ICU and deceased group was significantly lower than others. Likewise, Karan Sud et al. showed that 54% of their patients had LV dysfunction described as regional and/or global systolic dysfunction. This can be suggestive of ischemia due to large or small vessel obstruction, and a prothrombic state might be a prevalent mechanism of damage. Also, it raises the concern for potential direct cardiotoxicity by virus resulting in a decrease in myocardial function.^{14, 15} Identifying the pattern of organ involvement and illness progression course is one of the main purposes of ongoing clinical research about COVID-19. Based on the findings of the present study, it seems that ECG changes in patients with Covid-19, whether due to underlying heart disease or complications of the infection, can affect patient outcomes. Also, the findings of the present study showed that evaluation of changes in ECG, echocardiogram, and serum troponin could provide valuable information about the prognosis of patients with Covid-19.

7. Declarations

7.1. Conflict of Interests:

All authors declare that they have no conflict of interest.

7.2. Funding:

This research did not receive any specific grant from funding agencies in public, commercial or not-for-profit sectors.

7.3. Ethics approval and consent to participate:

The study protocol was in accordance with the guidelines of the 2013 version of the Helsinki Declaration and was approved by the ethics committee of Guilan University of Medical Sciences with the code number IR.GUMS.REC.1399.582. Informed consent for participation was obtained from all subjects.

1. Choudry, F. A.; Hamshire, S. M.; Rathod, K. S.; Akhtar, M. M.; Archbold, R. A.; Guttman, O. P.; Woldman, S.; Jain, A. K.; Knight, C. J.; Baumbach, A., High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology* **2020**, 76 (10), 1168-1176.
2. Benyounes, N.; Van Der Vynckt, C.; Tibi, S.; Iglesias, A.; Salomon, L.; Gout, O.; Tibi, T., Echocardiography in confirmed and highly suspected symptomatic COVID-19 patients and its impact on treatment change. *Cardiology research and practice* **2020**, 2020.
3. Pishgahi, M.; Yousefifard, M.; Safari, S.; Ghorbanpouryami, F., Electrocardiographic findings of COVID-19 patients and their correlation with outcome; a prospective cohort study. *Advanced Journal of Emergency Medicine* **2020**.
4. Judson, G. L.; Kelemen, B. W.; Njoroge, J. N.; Mahadevan, V. S., Cardiovascular implications and therapeutic considerations in COVID-19 infection. *Cardiology and Therapy* **2020**, 1-13.
5. Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S., Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine* **2020**, 382 (18), 1708-1720.
6. Richardson, S.; Hirsch, J. S.; Narasimhan, M.; Crawford, J. M.; McGinn, T.; Davidson, K. W.; Barnaby, D. P.; Becker, L. B.; Chelico, J. D.; Cohen, S. L., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *Jama* **2020**, 323 (20), 2052-2059.
7. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *Jama* **2020**, 323 (11), 1061-1069.
8. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA cardiology* **2020**, 5 (7), 802-810.

9. Chen, Q.; Xu, L.; Dai, Y.; Ling, Y.; Mao, J.; Qian, J.; Zhu, W.; Di, W.; Ge, J., Cardiovascular manifestations in severe and critical patients with COVID-19. *Clinical cardiology* **2020**, *43* (7), 796-802.
10. Denegri, A.; Pezzuto, G.; D'Arienzo, M.; Morelli, M.; Savorani, F.; Cappello, C. G.; Luciani, A.; Boriani, G., Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection. *Internal and Emergency Medicine* **2021**, 1-6.
11. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet* **2020**, *395* (10223), 497-506.
12. Rashid, M.; Wu, J.; Timmis, A.; Curzen, N.; Clarke, S.; Zaman, A.; Nolan, J.; Shoaib, A.; Mohamed, M. O.; de Belder, M. A., Outcomes of COVID-19-positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. *Journal of internal medicine* **2021**.
13. Bhatla, A.; Mayer, M. M.; Adusumalli, S.; Hyman, M. C.; Oh, E.; Tierney, A.; Moss, J.; Chahal, A. A.; Anesi, G.; Denduluri, S., COVID-19 and cardiac arrhythmias. *Heart rhythm* **2020**, *17* (9), 1439-1444.
14. Sud, K.; Vogel, B.; Bohra, C.; Garg, V.; Talebi, S.; Lerakis, S.; Narula, J.; Argulian, E., Echocardiographic findings in patients with COVID-19 with significant myocardial injury. *Journal of the American Society of Echocardiography* **2020**, *33* (8), 1054-1055.
15. Jain, S. S.; Liu, Q.; Raikhelkar, J.; Fried, J.; Elias, P.; Poterucha, T. J.; DeFilippis, E. M.; Rosenblum, H.; Wang, E. Y.; Redfors, B., Indications for and findings on transthoracic echocardiography in COVID-19. *Journal of the American Society of Echocardiography* **2020**, *33* (10), 1278-1284.

Table 1. Demographic and clinical characteristics of patients with COVID-19 by in-hospital mortality and ICU admission

		ICU admission			In-hospital mortality		
	Total (n=228) (%)	Non-ICU (n=212) (%)	ICU(n=16) (%)	P	Survived (n=212) (%)	Deceased (n=16) (%)	P
Demographics							
Age (years)	63.23 ± 13.59	62.85 ± 13.42	68.31 ± 15.33	0.121	63.21 ± 13.15	63.56 ± 19.06	0.943
Male Sex	125 (54.8)	114 (53.8)	11 (68.8)	0.246	115 (54.2)	10 (62.5)	0.522
Active smoking	67 (29.4)	60 (28.3)	7 (43.8)	0.253	61 (28.8)	6 (37.5)	0.460
Opium consumption	38 (16.7)	33 (15.6)	5 (31.2)	0.000	33 (15.6)	5 (31.2)	0.154
Comorbidities							
HF	16 (7.0)	14 (6.6)	2 (12.5)	0.311	13 (6.1)	3 (18.8)	0.090
VHD	3 (1.3)	3 (1.4)	0 (0)	1.000	3 (1.4)	0 (0)	1.000
IHD	25 (11.0)	20 (9.4)	5 (31.2)	0.020	22 (10.4)	3 (18.8)	0.395
COPD	2 (0.9)	2 (0.9)	0 (0)	1.000	2 (0.9)	0 (0)	1.000
CKD	8 (3.5)	7 (3.3)	1 (6.2)	0.447	7 (3.3)	1 (6.2)	0.447
CVA	8 (3.5)	7 (3.3)	1 (6.2)	0.447	7 (3.3)	1 (6.2)	0.447
DM	87 (38.2)	79 (37.3)	8 (50.0)	0.424	79 (37.3)	8 (50.0)	0.312
HLP	74 (32.5)	69 (32.5)	5 (31.2)	0.915	71 (33.5)	3 (18.8)	0.225
HTN	135 (59.2)	125 (59.0)	10 (62.5)	0.781	125 (59.0)	10 (62.5)	0.781
No. of comorbidities				0.059			0.149
0	50 (21.9)	50 (23.6)	0 (0)		49 (23.1)	1 (6.2)	
1	72 (31.6)	64 (30.2)	8 (50.0)		64 (30.2)	8 (50.0)	
≥ 2	106 (46.5)	98 (46.2)	8 (50.0)		99 (46.7)	7 (43.8)	
Cardiac intervention							
CAG	65 (28.5)	61 (28.8)	4 (25.0)	1.000	62 (29.2)	3 (18.8)	0.567
CABG	23 (10.1)	22 (10.4)	1 (6.2)	1.000	22 (10.4)	1 (6.2)	1.000
No. of symptoms				0.237			0.207
0	53 (23.2)	50 (23.6)	3 (18.8)		51 (24.1)	2 (12.5)	
1	116 (50.9)	110 (51.9)	6 (37.5)		109 (51.4)	7 (43.8)	

≥ 2	59 (25.9)	52 (24.5)	7 (43.8)		52 (24.5)	7 (43.8)	
Physiological parameters							
SBP	128.32 ± 24.81	129.49 ± 24.60	112.81 ± 22.87	0.009	130.20 ± 24.34	103.44 ± 16.50	<0.001
DBP	78.38 ± 12.63	79.03 ± 12.39	69.69 ± 12.97	0.004	79.20 ± 12.44	67.50 ± 10.00	<0.001
Temperature	36.96 ± 0.43	36.96 ± 0.44	36.90 ± 0.31	0.570	36.96 ± 0.44	36.97 ± 0.28	0.927
Respiratory Rate	19.07 ± 3.54	19.13 ± 3.32	18.31 ± 5.77	0.373	19.02 ± 3.13	19.81 ± 7.12	0.664
Heart Rate	85.60 ± 18.86	85.07 ± 18.53	92.62 ± 22.35	0.122	84.82 ± 18.60	95.94 ± 19.87	0.023
O2 sat	93.99 ± 6.53	94.33 ± 6.15	89.56 ± 9.54	0.067	94.43 ± 6.16	88.19 ± 8.49	0.011

Values are given as numbers (percentage) for categorical variables and mean ± standard deviation for continuous variables. Continuous variables are presented as mean (standard deviation (SD)) and compared using the independent t-test. Categorical variables are presented as numbers (percentages) and compared using the chi-square test.

HF; heart failure, VHD; valvular heart disease, IHD; ischemic heart disease, COPD; chronic obstructive pulmonary disease, CKD; chronic kidney disease, CVA; cerebrovascular accident, HLP; hyperlipidemia, HTN; hypertension, DM; diabetes, CAG; coronary angiography, CABG; coronary artery bypass graft, SBP; systolic blood pressure, DBP; diastolic blood pressure

Table 2. Echocardiographic and electrocardiographic(ECG) characteristics of patients with COVID-19 by in-hospital mortality and ICU admission

	Total (n=228)(%)	ICU admission			In-hospital mortality		
		Non-ICU (n=212)(%)	ICU (n=16)(%)	P	Survived (n=212)(%)	Deceased (n=16)(%)	P
Echocardiographic Findings							
Pericardial effusion	29 (12.7)	26 (12.3)	3 (18.8)	0.437	27 (12.7)	2 (12.5)	1.000
Pleural effusion	4 (1.8)	4 (1.9)	0 (0)	1.000	3 (1.4)	1 (6.2)	0.254
LV dilation	31 (13.6)	29 (13.7)	2 (12.5)	1.000	30 (14.2)	1 (6.2)	0.704
RV dilation	8 (3.5)	7 (3.3)	1 (6.2)	0.447	7 (3.3)	1 (6.2)	0.447
LV systolic dysfunction	108 (47.4)	98 (46.2)	10 (62.5)	0.299	98 (46.2)	10 (62.5)	0.209
LV diastolic dysfunction	11 (4.8)	10 (4.7)	1 (6.2)	0.559	10 (4.7)	1 (6.2)	0.559
LVH	32 (14.0)	32 (15.1)	0 (0)	0.137	30 (14.2)	2 (12.5)	1.000
Mitral regurgitation	173 (75.9)	161 (75.9)	12 (75.0)	1.000	159 (75.0)	14 (87.5)	0.369
Mitral stenosis	10 (4.4)	10 (4.7)	0 (0)	1.000	10 (4.7)	0 (0)	1.000
Tricuspid regurgitation	139 (61.0)	130 (61.3)	9 (56.2)	0.688	127 (59.9)	12 (75.0)	0.294
Aortic regurgitation	80 (35.1)	74 (34.9)	6 (37.5)	0.834	73 (34.4)	7 (43.8)	0.451
Pulmonary regurgitation	11 (4.8)	10 (4.7)	1 (6.2)	0.559	9 (4.2)	2 (12.5)	0.175
EF	36.14 ± 12.99	36.96 ± 12.72	25.31 ± 11.89	<0.001	36.98 ± 12.70	25.00 ± 12.38	<0.001
ECG Findings							
Heart Rate				0.005			<0.001
Normal	164 (71.9)	158 (74.5)	6 (37.5)		160 (75.5)	4 (25.0)	
Tachycardia	55 (24.1)	46 (21.7)	9 (56.2)		44 (20.8)	11 (68.8)	

Bradycardia	9 (3.9)	8 (3.8)	1 (6.2)		8 (3.8)	1 (6.2)	
Heart Rhythm				0.425			0.425
Sinus	200 (87.7)	187 (88.2)	13 (81.2)		187 (88.2)	13 (81.2)	
AF	28 (12.3)	25 (11.8)	3 (18.8)		25 (11.8)	3 (18.8)	
Axis				0.215			0.215
Normal	175 (76.8)	165 (77.8)	10 (62.5)		165 (77.8)	10 (62.5)	
Right or left deviation	53 (23.2)	47 (22.2)	6 (37.5)		47 (22.2)	6 (37.8)	
P wave (199=n)				1.000			0.337
Normal	193 (97.0)	180 (96.8)	13 (100)		181 (97.3)	12 (92.3)	
Abnormal	6 (3.0)	6 (3.2)	0 (0)		5 (2.7)	1 (7.7)	
PR interval (198=n)	156.26± 30.23	155.57± 30.36	166.15± 27.55	0.223	156.00± 30.13	160.00± 32.66	0.646
Pathologic Q wave	83 (36.4)	72 (34.0)	11 (68.8)	0.005	74 (34.9)	9 (56.2)	0.087
ST segment				0.636			0.935
Normal	66 (28.9)	61 (28.8)	5 (31.2)		62 (29.2)	4 (25.0)	
Elevation	96 (42.1)	88 (41.5)	8 (50.0)		89 (42.8)	7 (43.8)	
Depression	66 (28.9)	63 (29.7)	3 (18.8)		61 (28.8)	5 (31.2)	
T wave				0.166			0.393
Normal	91 (39.9)	82 (38.7)	9 (56.2)		83 (39.2)	8 (50.0)	
Abnormal (sharp, inverted, flat)	137 (60.1)	130 (61.3)	7 (43.8)		129 (60.8)	8 (50.0)	
Corrected QT interval (QTc)	412.46± 42.95	413.13± 42.83	403.56± 44.79	0.391	412.07± 41.74	417.69± 58.13	0.615
Block				0.555s			0.072
No	171 (75.0)	160 (75.5)	11 (68.8)		162 (76.4)	9 (56.2)	
YES	57 (25.0)	52 (24.5)	5 (31.2)		50 (23.6)	7 (43.8)	

Values are given as numbers (percentage) for categorical variables and mean ± standard deviation for continuous variables. Continuous variables are presented as mean (standard deviation (SD)) and compared using the independent t-test. Categorical variables are presented as numbers (percentages) and compared using the chi-square test.

LV; left ventricle, RV; right ventricle, LVH; left ventricular hypertrophy, EF; ejection fraction, AF; atrial fibrillation.